Ljiljana Minwalla is a business and IP lawyer with over 18 years of industry experience advising early- to late-stage biotechnology companies through complex legal environments. Ljiljana has worked across multiple modalities, technologies and therapeutic indications. Currently, she provides broad, cross-functional consulting services to companies across the life sciences. She was most recently SVP, BD & Legal Affairs, Corporate Secretary at Cygnal Therapeutics, a Flagship company. Prior to that role, Ljiljana served in various roles of increasing responsibilities at CiVi Biopharma, Helsinn Therapeutics, IAVI, Mesoblast and Protein Sciences Corporation, where she served as Corporate Secretary & General Counsel.
Ljiljana is experienced in advising biotech companies on a broad range of matters including IP strategy & portfolio management, oppositions & IPRs, commercial transactional, licensing, M&A, alliance management, asset integration, labor and employment issues, corporate governance, regulatory compliance, clinical trial oversight, CROs, CMC, QA, litigation, and development of training programs. As a strategic partner, Ljiljana actively advises senior management and Boards on these areas, minimizing risks without impeding business objectives.
Ljiljana holds a Bachelor of Science in Chemistry, a Ph.D. in Pharmacology and a JD from Brooklyn Law School. She is licensed to practice in New York and Pennsylvania, and is registered to practice before the United States Patent and Trademark Office.